One study by Zhang et al., a single-arm study with 11 participants with N2 ALK-rearranged NSCLC, found a 90.9% ORR in patients receiving neoadjuvant crizotinib for a median duration of 30 days (range 28–120), and two patients (18.2%) achieved a pCR [73]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.